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ABSTRACT We have investigated the molecular basis of
human immunodeficlency virus type 1 (HIV-1) latency In a
tissue culture model and In HIV-infected people. We show that
increased levels of Tat, but not Rev, can release the proviruses
from latency in U1 cells. The absence of Tat in these cells is
manifested by the accumulation of promoter-proximal viral
transcripts, whereas the presence of Tat correlates with in-
creased expression of viral proteins and an increase in pro-
moter-distal tnscripts. The presence of promoter-proximal
transcripts also serves as a marker for latency in humans. We
observed the exclusive presence of promoter-proximal viral
transcripts in peripheral mononuclear cells from the majiority
(10/11) of asymptomatic IlV-infected individuals examined.
Activation of these cells in vigro, and viremia in vivo, correlated
with a switch from promoter-proimal anscription to pro-
moter-distal ascription. These results suggest that the con-
trol between latency and replication ofHIV in vivo is at the level
of transcription elongation.
Although the progression from sero-conversion to the ac-
quired immunodeficiency syndrome (AIDS) frequently takes
years, viral replication occurs at all stages of the infection
(1-4). In particular, high levels of virus can be detected in
lymph nodes during the asymptomatic stages of disease
progression (4, 5). Nonetheless, the fact that there is persis-
tent replication of human immunodeficiency virus (HIV)
even in stages of clinical latency does not mean that individ-
ual cells do not harbor latent proviruses (called "cellular
latency"). Indeed, individual infected cells harbor proviruses
that are not expressed until further cellular activation (6-8).
Moreover, large numbers of latently infected cells can be
detected both in lymph nodes (5) and in the blood before the
actual onset of AIDS (4).
U1 cells (9) have been used as a convenient tissue culture
model of HIV-1 latency because their proviruses are poorly
expressed until cellular activation by a number of cytokines/
lymphokines or phorbol esters that act through the cellular
transcription factor NF-#cB (reviewed in ref. 10). U1 cells are
derived from U937 cells, which represent immature human
CD4-positive monocytes (11), and contain two integrated
HIV-1 proviruses.
Here, we find that constitutive expression of the viral
protein Tat induces the expression of all major viral tran-
scripts and proteins in U1 cells, whereas the viral protein Rev
has no effect. This suggests that U1 cells are held in latency
because of a lack of Tat protein. We developed a reverse
transcription-polymerase chain reaction (RT-PCR) method
to detect the short, promoter-proximal transcripts that are
made from the viral long terminal repeat (LTR) in the absence
of Tat and showed that U1 cells synthesize large amounts of
promoter-proximal transcripts relative to promoter-distal
transcripts. Cellular activation with phorbol esters, or intro-
duction of Tat alone, increased the relative abundance of
promoter-distal transcripts.
We used this RT-PCR assay to determine the transcrip-
tional state of proviruses of HIV-infected individuals in vivo.
In 10 of 11 HIV-infected individuals with high CD4 levels
(>400), promoter-proximal transcripts could be readily de-
tected in the absence of promoter-distal transcripts in pe-
ripheral blood mononuclear cells (PBMCs). Activation in
culture of latently infected cells from an asymptomatic HIV-
infected individual correlated with virus production and the
induction of promoter-distal transcription. These results in-
dicate that cellular latency by HIV in vivo can be detected by
the presence of transcriptionally active proviruses that tran-
scribe only promoter-proximal viral RNA.
MATERIALS AND METHODS
Cells. U1 cells were grown in RPMI medium with 10%o calf
serum and antibiotics. PBMCs were separated from antico-
agulated whole blood with Sepracell-MN (Sepratech, Okla-
homa City, OK). When cultured, 4 x 106 cells were added to
4 ml of RPMI medium with 20% fetal bovine serum, 5%
interleukin 2, and 0.12% Polybrene. One microgram of phy-
tohemagglutinin (PHA) per ml and 50 ng of phorbol 12-
myristate 13-acetate (PMA) per ml were added to the medium
to stimulate PBMCs or U1 cells.
Reverse Transcription and PCR. RNA and DNA were
isolated from 2 x 106 cultured cells orfreshly isolated PBMCs
as described (12). RNA and DNA were serially diluted
separately in water with 1 pg of tRNA per ml. Each serial
dilution was separately amplified. cDNA synthesis was per-
formed with random primers in a 20-t4 reaction volume. A
commercially available PCR carry-over prevention kit, and
the "hot-start" system Ampli-wax (Perkin-Elmer/Cetus),
was also added to each sample and cDNAs were amplified in
afinal volume of 100 td in an amplification mixture containing
1 unit of Taq polymerase, 1 unit of uracil N-glycosylase,
Abbreviations: AIDS, acquired immunodeficiency disease syn-
drome; HIV, human immunodeficiency virus; LTR, long terminal
repeat; PBMC, peripheral blood mononuclear cell; RT-PCR, reverse
transcription-polymerase chain reaction; MuLV, murine leukemia
virus; PHA, phytohemagglutinin; PMA, phorbol 12-myristate 13-
acetate.
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FIG. 1. Structure ofretroviral vectors. Vectors were based on the
MuLV genome as described (15). Open boxes represent the LTRs;
black boxes represent the simian virus 40 early promoter, striped
boxes are either the tat cDNA or the rev cDNA, and NEO is the
G418-resistance gene. There was a 50-fold increase in chloramphen-
icol acetyltransferase activity in U937 cells infected with LTatSN
compared with U937 cells infected with LXSN when both were
transiently transfected with a plasmid containing an HIV-1 LTR 5' to
the cat gene. There was a >200-fold increase in p24P8 in U937 cells
infected with LrevSN compared with U937 cells infected with
LneoSN when both were transiently transfected with a HIV-1
provirus containing a frame-shift mutation in the second exon ofRev.
0.8-1.0 pmol of each primer, 200 pM (each) dATP, dGTP,
and dCTP, 100 AM dUTP, 10mM Tris (pH 8.3), 3 mM MgCl2,
50 mM KCl, and 200 ,ug of gelatin per ml, for 30 cycles using
a thermal profile for 20 sec at 95°C, for 20 sec at 56°C, and for
40 sec at 72°C. Sequences ofprimers and probes were derived
from the HIV-1..j LTR. They were as follows: primer 1,
GGGTCTCTCTGGTTAGA (positions 1-16); primer 2,
GGGTTCCCTAGTTAGCC (positions 58-42); primer 3, CT-
GCTAGAGATTTTCCACACTGAC (positions 181-158),
where + 1 is the first base of R.
The amplified product of primer pairs 1 and 2 was 59 bp in
length and the product of primer pairs 1 and 3 was 182 bp in
length. Amplified products were detected by liquid hybrid-
ization as described (13). Each sample was separately am-
plified but electrophoresed in 10%o nondenaturing polyacryl-
amide gels and hybridized together in the same lanes for ease
of comparison. The radiolabeled probe was complementary
to the TAR loop region of the HIV-1 LTR: TAR loop probe,
GCCTGGGAGCTCTCTGG (positions 27-43).
The probe was end-labeled with [y-<32P]ATP and added to
a final concentration of 30 pmol to samples that were dena-
tured for 1 min at 950C and hybridized for 3 min at 56°C.
Some samples were done by an alternative protocol that
has equal sensitivity and specificity but is more rapid.
Briefly, simultaneous RNA and DNA isolation was done





ratories, Houston), and RNA samples were treated with
DNase I. Primer 1 (above) was end-labeled with [y-32P]ATP
and gel purified. The PCR Gem-mediated hot-start technique
(Perkin-Elmer) was used to increase the specificity of the
amplification. PCR reactions were carried out for 25 cycles,
and one-fifth of the products were loaded on a 8% denaturing
polyacrylamide gel that was run at 25 mA for 2 hr, dried, and
exposed to film. Negative controls without RT were per-
formed for all samples in addition to an RNA standard.
RESULTS
Tat Expression Induces the HIV-1 Proviruses in U1 Cells in
the Absence of Cellular Activation. To gain insight into the
molecular basis of latency in HIV-infected people, we first
investigated a tissue culture model of cellular latency. The
activation of U1 cells by phorbol esters has been shown to
increase levels of total viral RNA and especially of larger
singly spliced and unspliced viral transcripts (14). To deter-
mine if the maintenance of proviral latency in U1 cells is due
to insufficient levels of a viral gene product, specifically Tat
or Rev, we tested whether or not the increased expression of
Tat or Rev from heterologous promoters could induce these
proviruses in U1 cells. To this end, retroviral vectors that
expressed either Tat or Rev ofHIV-1 were constructed using
the genome of the murine leukemia virus (MuLV) (Fig. 1).
High titer viral stocks were obtained that could infect human
epithelial and lymphoid cell lines and transfer functional Tat
or Rev into these cells (Fig. 1 and ref. 15).
After infection with retroviral vectors that contained Tat or
Rev, viral replication was assessed by measuring levels of
secreted p24w in culture supernatants of U1 cells (Fig. 2A).
Some cultures were also infected with wild-type amphotropic
MuLV to control for possible effects ofMuLV proteins (Fig.
2). Infections of U1 cells with the wild-type MuLV and the
retroviral vector encoding Rev did not increase levels of
p24Pm (Fig. 2A). On the other hand, infections with the
retroviral vector encoding Tat led to rapid and sustained
increases in levels of p24w. By day 8 after infection, these
levels were 100-fold higher than in the control U1 cells and
were nearly equivalent to that observed with PMA (Fig. 2A).
Uninfected U1 cells express small amounts of doubly
spliced viral mRNAs (Fig. 2B, lane 1). We found that Tat
alone increased the total amounts of viral RNA and increased
levels of singly spliced and genomic viral transcripts relative
to those of doubly spliced mRNAs (Fig. 2B, lane 2). On the
B






FIG. 2. Effects of Tat on the expression of viral proteins in U1 cells. (A) Tat brings U1 cells out of latency. U1 cells (1 X 106) were infected
with 2 X 105 G418 transforming units of virus (for LtatSN and Lrev SN) or with 1 x 106 TCID50 units of wild-type MuLV. An aliquot of cells
was also treated with PMA/PHA. The y axis is a logarithmic scale. e, LtatSN-infected cells; o, LrevSN-infected cells; *, wild-type amphotropic
MuLV-infected cells; o, PHA/PMA-treated cells. (B) Seven days after infection, RNA was collected from cultures infected with the same
retroviral vectors as inA. Ten micrograms oftotalRNA was loaded per lane. Lane 1, unstimulated U1 cells; lane 2, U1 cells infected with LtatSN;
lane 3, U1 cells infected with LrevSN; lane 4, U1 cells infected with wild-type MuLV. Sizes ofthe majorRNA species, which represent genomic,
env, and multiply spliced viral transcripts are marked.
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other hand, the quantity and splicing patterns of these
mRNAs did not change when rev or neo genes were intro-
duced into these cells (Fig. 2A, lanes 3 and 4). These data
indicate that constitutive expression of Tat induces the
expression of integrated proviruses and can substitute for
cellular activation ofU1 cells. Thus, the previously observed
phenotype of increased expression of singly spliced and
genomic viral transcripts that followed cellular activation of
U1 cells (14) probably reflected the increased synthesis of
Rev that occurred after sufficiently high levels of Tat were
achieved.
The presence of functional Tat in activated and nonacti-
vated U1 cells was indirectly assayed by fusing U1 cells with
polyethylene glycol to an indicator cell line that contained a
single integrated copy of the HIV-1 LTR linked to the
P-galactosidase reporter gene that is sensitive to levels of Tat
(16). The results of these experiments (not shown) demon-
strated that nonactivated U1 cells express little Tat but that
cellular activation increases the synthesis of Tat. This sug-
gests that activation of U1 cells by phorbol esters acts, at
least in part, through increasing Tat levels.
Tat Affects the Ratio of Promoter-Proximal to Promoter-
Distal Viral Transcripts in Ul Cells. Nuclear run-on experi-
ments demonstrated a steep polarity of HIV-1 transcription
from the LTR that was reversed by Tat (17-20). These
transcriptional states were reflected in the accumulation of
short, prematurely terminated TAR transcripts in the ab-
sence of Tat and of long polyadenylylated viral transcripts in
the presence ofTat (18,21). Given our results that insufficient
levels of Tat were indicative of proviral latency in U1 cells
(Fig. 2), we tested whether these different viral RNAs could
be used as markers for proviral latency.
To determine levels of short and long viral transcripts, we
used quantitative RT-PCR (12, 13). First, pairs ofprimers that
corresponded to 5' and 3' ends ofTAR (primers 1 and 2) and
to the 3' end of the U5 region (primer 3) were synthesized
(Fig. 3A). Primers 1 and 2 would amplify both short and long
transcripts, while primers 1 and 3 would amplify only RNA
that was longer than the TAR region (Fig. 3A). Given the
steep transcriptional polarity in the absence of Tat, and the
fact that only prematurely terminated transcripts that contain
the TAR RNA stem-loop are stable in cells (17, 19, 22), the
second set ofprimers (1 and 3) should detect very few, if any,
prematurely terminated transcripts. Both sets of primers
amplified with equal efficiencies in vitro transcribed RNA
and plasmid DNA and were sensitive to <100 copies of
nucleic acid (Fig. 3B and data not shown).
Ratios of short to long transcripts were assessed by com-
paring autoradiographs of amplified DNA obtained with both
sets of primers (Fig. 3B, left). Nonactivated U1 cells tran-
scribed predominantly short transcripts (Fig. 3B, righthand
panel). This correlated with the low levels of doubly spliced
transcripts in U1 cells (Fig. 2B, lane 1). However, 4 and 8
days after infection with amphotropic retroviruses coding for
Tat (Fig. 1), ratios of short to long transcripts decreased by
10- to 100-fold (Fig. 3B, central panels). Moreover, 4 days
after the administration of PHA/PMA, the ratios of short to
long transcripts decreased similarly (Fig. 3B, righthand pan-
el). Activation of U1 cells with PMA led to a more rapid
qualitative change in HIV-1 transcription, which suggests
that activated U1 cells expressed Tat earlier than those
infected with amphotropic retroviral vectors. These experi-
ments suggest that escape from viral latency is accompanied
by Tat-mediated increase in elongation efficiency of RNA
polymerase II.
Detection ofPromoter-Proximal Transcripts inPBMCs from
H1-Infocltd Individuals with High CD4 Levels. Because of
the concordance between assays ofTat function and RT-PCR
in U1 cells, we next asked whether RT-PCR could be used to
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FIG. 3. Detection of transcripts initiated from the HIV-1 LTR in
U1 cells by RT-PCR. (A) Schematic representation of the HIV-1
LTR, oligonucleotide primers used to amplify viral transcripts, and
expected sizes of PCR products. The three primers are shown above
the boxes representing U3, R, and U5 regions of the HIV-1 LTR
(TAR is contained within R). Short, prematurely terminated, non-
polyadenylylated transcripts (ST) of 59 nucleotides and long tran-
scripts (LT) of 182 nucleotides, which are amplified by primer pairs
1 and 2 and 1 and 3, respectively, are diagramed below the HIV-1
LTR. The filled box represents the TAR region. (B) Ratios of short
to long transcripts in U1 cells infected with retroviruses encoding Tat
and treated with PHA/PMA. Ten-fold dilutions of plasmid DNA
amplified with both primer pairs are shown on the left. On the right,
RNA from U1 cells was amplified with the primer pairs shown in A.
dO, Nonactivated U1 cells; TAT d4, U1 cells 4 days after infection
with LtatSN (Fig. 1); Tat d8, U1 cells 8 days after infection with
LtatSN; PHA/PMA d4, U1 cells 4 days after stimulation with PHA
and PMA. Ratios ofthe long transcripts (LT) to short transcripts (ST)
are given below each lane.
infected individuals. To this end, RNA and DNA were
extracted from PBMCs of 9 HIV-1-infected individuals with
high CD4 levels (CD4 cells per mm3 ranged from 1051 to 502,
with a median level of 620). None of these individuals was
viremic, and all were asymptomatic except for oral candida
in two individuals.
In all nine cases, viral DNA could be amplified from cells
of these individuals with both primer pair 1 and 3 (Fig. 4C)
and primer pair 1 and 2 (Fig. 4D). This indicates that the
PBMCs of each individual harbored HIV-infected cells.
Moreover, in all nine cases the presence of promoter-
proximal transcripts (short transcripts) could be readily de-
tected (Fig. 4B) in the absence of promoter-distal transcrip-
tion (Fig. 4A). Controls of the reactions without reverse
transcriptase verified that the promoter-proximal signal was
due to RNA rather than DNA (Fig. 4B, lanes marked with a
minus sign). This result indicates all (9/9) of these non-AIDS
individuals with high CD4 counts harbored latent proviruses
that were transcriptionally active, but deficient in transcrip-
tion elongation.
To determine if, as in U1 cells, activation of latently
infected cells could change the ratio of promoter-proximal to
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FIG. 4. Analysis ofHIV-1 transcripts in PBMCs of infected individuals with high CD4 counts. RNA and DNA were isolated from buffy coats
of individuals labeled 1-9 and subjected to PCR in the presence or absence of reverse transcriptase (see text). (A) RT-PCR with primer pair 1
and 3 (long transcripts, Fig. 3A) using an RNA template from the PBMCs of individuals 1-9. The lane marked U1 is RNA from activated U1
cells. (B) RT-PCR with primer pair 1 and 2 (short transcripts, Fig. 3A) using an RNA template from the PBMCs of individuals 1-9. The lanes
marked U1 are RNA from activated U1 cells. The minus or plus sign indicates whether or not reverse transcriptase was added to the reaction
prior to the PCR. (C) PCR with primer pair 1 and 3 using a DNA template from the PBMCs of individuals 1-9. HL60 is DNA from HL60 cells
as a negative control. (D) PCR with primer pair 1 and 2 using a DNA template from the PBMCs of individuals 1 through 9. CD4 counts of
individuals 1-9 were 1051, 636, 545, 771, 595, 620, 840, 546, and 505, respectively. All patients had received AZT except no. 9.
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Is of one individual on days 3 and 14 after cellular activation, respectively). RNA
I by coculture with was also extracted from PBMCs of two AIDS patients with
As in Fig. 4, only CD4 counts of 10 and 36 (Fig. 5). As expected, because of
detected in these increased levels of viral replication observed late in the
or, after activation, disease (23, 24), the ratio of short to long transcripts in these
A to <10-fold (Fig. patients approached one (Fig. 5). Promoter-distal transcripts
)ng transcripts were could also be detected in the PBMCs ofan asymptomatic and
f p24w* in culture p24w negative individual with a CD4 count of 412 (Fig. 5).
(ml and >100 pg/ml These results indicate that cellular latency in vivo can be
detected by the presence of promoter-proximal transcripts
412 10 36 and that activation of proviruses, either in culture or in vivo
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DISCUSSION
We show that the HIV-1 provirus in U1 cells can be released
from latency by an increase in the intracellular level of the
viral transactivator, Tat. The absence of Tat is correlated
with a predominance of promoter-proximal transcripts over
; .̂ promoter-distal transcripts. The addition of Tat alone, or
*w"t | stimulation of the cells with phorbol esters, changes the ratio
of promoter-proximal to promoter-distal transcripts. These
results allowed us to develop an assay for the detection of
HIV cellular latency in infected people.
1:10 1:10 1:100 1:10 1:1 The molecular basis of HIV-1 latency in cells can beexplained by blocks at several stages of the viral life cycle.
tently infected cells results in promoter- There is evidence to support incompletely reverse tran-
R products from PBMCs of infected but scribed RNA (25), unintegrated proviral DNA (7), and inte-
)4 counts of 420 and 412) and AIDS grated proviruses that are either transcriptionally silent or
and 36) are shown. The asymptomatic express only doubly spliced viral mRNAs (26). Our study
stage I and were not receiving antiviral suggests the existence of another state in which promoter-
od was taken. The AIDS patients were proximal transcription from the HIV-1 LTR predominates.
tage VI and were receiving 3'-azido-3'- These states of viral latency and replication are distinguished
e time the blood was taken. PBMCs from elongatioficient andelnaicompete transcrd(CD4 count 420) were activated with by elongation-deficient and elongation-competent transcrip-
or by cocultivation with stimulated feeder tion complexes that produce short transcripts and long tran-
long to short transcripts (LT:ST) were scripts, respectively. In all individuals with a CD4 count
Ire shown under each lane. above 500 studied here, the presence of promoter-proximal
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transcripts could be detected in the absence of promoter-
distal transcripts.
In Ul cells, and in the PBMCs of an asymptomatic HIV-
1-infected individual, cellular activation correlated with de-
creased ratios of short to long transcripts and new synthesis
of viral proteins. We also observe this phenotype in AIDS
patients and in one HIV-infected individual with an interme-
diate CD4 level (Fig. 5). It is possible that detection of
promoter-distal transcripts might be a reflection ofthe escape
of the activated infected cells from the lymph nodes and,
therefore, detection ofpromoter-distal transcripts might be a
sensitive marker for the destruction ofthe follicular dendritic
cell networks that occurs early in disease progression (re-
viewed in ref. 27).
Various mechanisms have been proposed to explain the
regulation of assembly of elongation-competent polymerase
complexes (28). Presumably, in latently infected cells that
transcribe only promoter-proximal viral RNA, the basal
levels ofNF-KB (or other transcription factors that act on the
LTR) are so low that levels ofTat are not reached that would
affect a change from promoter-proximal to promoter-distal
transcription. This might occur in T cells that were once
activated such that viral integration occurred (25, 29) but then
became quiescent and part ofthe pool ofinfected "memory"
T cells. Indeed, these T cells as defined by the CD45RO
marker contain abundant proviral DNA (30, 31). Activation
of these cells by antigen would increase the basal level of
transcription from the LTR, which, in turn, would increase
the level of Tat and activate proviral expression. Given that
increased levels of viremia are observed late in the disease
(23, 24), it is possible that transcriptional activation of these
latent proviruses in the periphery plays a role in T-cell
depletion and in the progression to AIDS.
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